p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration
51.4% of Patients Would Consider Using GLP-1 Drugs Again 51.4% of participants said they would use GLP-1s again
Dehydration Risk Reduced appetite on GLP-1 medications often extends to reduced thirst
Supporting this notion, MS interactomic analyses of GLP-1R co-immunoprecipitates in INS-1 832/3 SNAP/FLAG-hGLP-1R cells after a 5-minute stimulation with the endogenous agonist GLP-1, as well as with the exendin-4-based biased GLP-1RAs exendin-F1 and exendin-D3, previously shown to trigger differing degrees of GLP-1R internalisation 18,19 , resulted in marked differences in the propensity of the receptor to associate with VAPB (Supplementary Fig
"They're grappling with health outcomes how to get their population healthier [while] controlling costs, and GLP-1s could be a part of gaining those outcomes then thirdly, they're grappling with employee value proposition how do I continue to compete in what is still a competitive employer market?" Read more: Most benefit leaders see these concerns as being at odds with each other, Walmsley said, but they don't have to be
PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways
